In the tumor microenvironment, nivolumab binds and blocks PD-1 on the surface of the T cells, which results in the fewer PD-1/PD-L1 and PD-1/PD-L2 engagements in the immunological synapse between T cells and cancer cells (Fig. 2f). The gene discussed is PDCD1LG2; the disease is cancer.